Coexistence of chronic myelogenous leukemia and chronic lymphocytic leukemia

Schreiber, Zwi A.; Axelrod, Morton R.; Abebe, Lool

doi:10.1002/1097-0142(1984)54:4<697::aid-cncr2820540417>3.0.co;2-c

Cited by 24 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are few reports of secondary CML following chemotherapy; we identified sixteen [1,4,9,11,13,16,19,24,27,29,34,35,37,38]. These cases are summarized in Table 2.…”

Section: Discussionmentioning

confidence: 99%

A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma

Nakamura

Inokuchi

Hanawa

et al. 2000

Annals of Hematology

View full text Add to dashboard Cite

We report here a very rare case of chronic myeloid leukemia (CML) with a minor bcr-abl transcript, which developed following long-term chemotherapy with fluorouracil for esophageal carcinoma. A 64-year-old male patient was diagnosed with CML. Four years earlier, he had suffered from esophageal carcinoma, which was treated by surgical resection followed by oral administration of fluorouracil (200 mg/day) for 4 years. Molecular analysis of his Philadelphia chromosome (Ph) using reverse-transcriptase polymerase chain reaction (RT-PCR) and subsequent sequencing revealed a minor bcr-abl transcript. The clinical course of this patient was aggressive with a short chronic phase of CML. This is the first reported case of secondary CML with a minor bcr-abl transcript.

show abstract

“…There are few reports of secondary CML following chemotherapy; we identified sixteen [1,4,9,11,13,16,19,24,27,29,34,35,37,38]. These cases are summarized in Table 2.…”

Section: Discussionmentioning

confidence: 99%

A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma

Nakamura

Inokuchi

Hanawa

et al. 2000

Annals of Hematology

View full text Add to dashboard Cite

show abstract

“…The spectrum of secondary solid neoplasms during the course of CLL includes carcinomas of the skin, stomach, colon, breast, or kidney [4, 5]; among secondary hematologic malignancies, cases of acute lymphocytic, myelocytic, monocytic and myelomonocytic leukemia, erythroleukemia, plasma cell leukaemia [6], and myeloproliferative neoplasms (MPN) have been reported [7–54].…”

Section: Introductionmentioning

confidence: 99%

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

Laurenti¹,

Tarnani²,

Nichele

et al. 2011

American J Hematol

View full text Add to dashboard Cite

Although the coexistence of chronic lymphocytic leukemia (CLL) and myeloproliferative neoplasms (MPN) has been sporadically reported in the literature, no systematic studies on this disease association are available. We retrospectively analyzed 46 patients affected by CLL/MPN referred by 15 Italian GIMEMA centers. The aim of this retrospective multicenter study was to define the following: clinico-biological characteristics, possible familiarity, clinical course of both diseases, and influence of MPN chemotherapy on the course of CLL. Among 46 patients, 30 patients were males, 16 patients were females; median age was 71 years. Only one case had familiar CLL. Myeloproliferative disorders consisted of essential thrombocytemia in 18 cases, polycythemia vera in 10 cases, chronic myeloid leukemia in 9 cases, primary myelofibrosis in 6 cases, and MPN/myelodysplastic syndrome in 3 cases. The lymphoproliferative disorder was diagnosed as monoclonal B-cell lymphocytosis in 8 patients and as Binet Stage A CLL in 38 patients. After a median follow-up of 49 months, 9 patients experienced progressive CLL and only 6 patients required treatment after a median of 57.5 months. The biological profile confirmed a subset of low-risk CLL. Twenty patients received chemotherapy for MPN without influence on the course of CLL: lymphocyte counts remained unchanged after 3, 6, and 12 months of treatment. This series is the largest so far reported in literature. The diagnosis of concomitant CLL/MPN is a rare event and lymphoproliferative disorders present a clinical indolent course with a low-risk biological profile. MPN therapy does not interfere with the prognosis of patients with CLL. Am. J. Hematol. 2011. (c) 2011 Wiley-Liss, Inc

show abstract

“…A higher frequency of melanomatous and nonmelanomatous skin cancer, as well as of lung cancer and adenocarcinoma of the GI tract, has also been described [7]. Although the majority of patients with CLL who developed CML had received either RT or alkylating agents (chlorambucil) (np8) [4,26,62,78,102,109,123,124], four cases of secondary CML in untreated patients have also been reported (Table 2) [45,92,123,124]. The median interval to development of CML was 30 months (range 17-53 months), which is similar to that reported in a recent study on HCL patients treated for their disease, with a peak incidence of secondary malignancies within the first 2 years after ID of HCL [7].…”

Section: Preclinical Phase Of CMLmentioning

confidence: 99%

“…However, only two were treated with CT alone. Apart from these two cases another 12 patients with tr-CML after CT alone have been reported (Table 4) [4,26,43,62,69,85,95,102,109,117,121,124]. The median time from ID of the primary malignancy to CML was 66 months (range 18-150 months).…”

Section: The Role Of Irradiation and Radiotherapy In The Development mentioning

confidence: 99%

See 1 more Smart Citation

Treatment-related chronic myelogenous leukemia

Waller

Fetscher

Lange

1999

Annals of Hematology

View full text Add to dashboard Cite

Treatment-related (Tr) AML and MDS after chemotherapy, radiotherapy, or the combination of both have been well characterized. However, tr-CML seems to differ from these better-known entities in frequency, clinical course, and prognosis. Tr-CML cannot be distinguished from de novo CML cytogenetically, and, in contrast to tr-AML and tr-MDS, typical chromosomal aberrations related to tr-CML have not been described. Treatment-related CML is a late effect of cytotoxic or immunosuppressive therapy which might be increasingly recognized due to a higher number of patients treated with intensive therapy regimens. We review here the available data on incidence of tr-CML as well as the affected individual's characteristics with regard to different treatment options in malignant and nonmalignant diseases.

show abstract

Coexistence of chronic myelogenous leukemia and chronic lymphocytic leukemia

Cited by 24 publications

References 19 publications

A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma

A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

Treatment-related chronic myelogenous leukemia

Contact Info

Product

Resources

About